Evommune, Inc. EVMN
7.04 USD -0.20 (-2.76%)
Regular-session close
7.04 0.00 0.00%
After hours · Nov 20, 4:01 PM ET
6.96 Day range 7.24
5.10 52-week range 31.57
- YTD
- -58.88%
- 1 year
- -62.37%
5D -0.81 (-10.06%)
- Market cap
- 291.10M
- EPS (ttm)
- -3.83
- YTD return
- -58.88%
- 1-year return
- -62.37%
- Volume
- 549.40K
- Avg volume
- 838.16K
- Open
- 7.10
- Previous close
- 7.24
- Day's range
- 6.96 – 7.24
- 52-week range
- 5.10 – 31.57
Fundamental scorecard
4 of 25 checks passed on EVMN’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
EVMN Revenue — quarterly 0
EVMN Net income — quarterly -30.88M
EVMN EPS — quarterly -0.85
News
Needham Maintains Buy on Evommune, Lowers Price Target to $25
Evommune Q3 EPS $(0.85) Misses $(0.84) Estimate
Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Evommune to Present at Upcoming Investor Conferences
Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development
Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
Evommune Announces $30 Million Private Placement Evommune Receives Exclusive License From Hinova Pharmaceuticals To Develop, Manufacture, Commercialize EVO570 Outside China; Hinova To Get $30M Upfront Payment
Your note
Sign in to keep a note on EVMN — it syncs with the Stock Master app.
